Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Prices Upsized $300M Public Offering

NEW YORK – Twist Bioscience announced on Wednesday after the close of the market the pricing of an upsized $300 million public offering of common stock at $110 per share.

The South San Francisco, California-based firm will offer approximately 2.8 million shares, including 75,000 shares to be sold by certain shareholders.

Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares at the public offering price, less the underwriting discount and commissions.

Twist initially said it planned to offer $250 million worth of shares. It expects the offering to close on or about Dec. 7, 2020, subject to customary closing conditions. Twist will not receive any proceeds from the sale of shares by the selling stockholders.

This is the third stock offering this year for the company after it raised more than $230 million in public offerings in February and June.

In morning trading on the Nasdaq, shares of Twist were up 4 percent at $119.93.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.